A multivalent T-antigen-based vaccine for Group A Streptococcus
Abstract Pili of Group A Streptococcus (GAS) are surface-exposed structures involved in adhesion and colonisation of the host during infection. The major protein component of the GAS pilus is the T-antigen, which multimerises to form the pilus shaft. There are currently no licenced vaccines against...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-02-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-83673-4 |
| _version_ | 1818856060767698944 |
|---|---|
| author | Jacelyn M. S. Loh Tania Rivera-Hernandez Reuben McGregor Adrina Hema J. Khemlani Mei Lin Tay Amanda J. Cork Jeremy M. Raynes Nicole J. Moreland Mark J. Walker Thomas Proft |
| author_facet | Jacelyn M. S. Loh Tania Rivera-Hernandez Reuben McGregor Adrina Hema J. Khemlani Mei Lin Tay Amanda J. Cork Jeremy M. Raynes Nicole J. Moreland Mark J. Walker Thomas Proft |
| author_sort | Jacelyn M. S. Loh |
| collection | DOAJ |
| description | Abstract Pili of Group A Streptococcus (GAS) are surface-exposed structures involved in adhesion and colonisation of the host during infection. The major protein component of the GAS pilus is the T-antigen, which multimerises to form the pilus shaft. There are currently no licenced vaccines against GAS infections and the T-antigen represents an attractive target for vaccination. We have generated a multivalent vaccine called TeeVax1, a recombinant protein that consists of a fusion of six T-antigen domains. Vaccination with TeeVax1 produces opsonophagocytic antibodies in rabbits and confers protective efficacy in mice against invasive disease. Two further recombinant proteins, TeeVax2 and TeeVax3 were constructed to cover 12 additional T-antigens. Combining TeeVax1–3 produced a robust antibody response in rabbits that was cross-reactive to a full panel of 21 T-antigens, expected to provide over 95% vaccine coverage. These results demonstrate the potential for a T-antigen-based vaccine to prevent GAS infections. |
| first_indexed | 2024-12-19T08:18:30Z |
| format | Article |
| id | doaj.art-e5c26595d82b49ec87d8e1591a0db673 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-19T08:18:30Z |
| publishDate | 2021-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-e5c26595d82b49ec87d8e1591a0db6732022-12-21T20:29:27ZengNature PortfolioScientific Reports2045-23222021-02-0111111010.1038/s41598-021-83673-4A multivalent T-antigen-based vaccine for Group A StreptococcusJacelyn M. S. Loh0Tania Rivera-Hernandez1Reuben McGregor2Adrina Hema J. Khemlani3Mei Lin Tay4Amanda J. Cork5Jeremy M. Raynes6Nicole J. Moreland7Mark J. Walker8Thomas Proft9Department of Molecular Medicine & Pathology, School of Medical Sciences, The University of AucklandAustralian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of QueenslandDepartment of Molecular Medicine & Pathology, School of Medical Sciences, The University of AucklandDepartment of Molecular Medicine & Pathology, School of Medical Sciences, The University of AucklandDepartment of Molecular Medicine & Pathology, School of Medical Sciences, The University of AucklandAustralian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of QueenslandDepartment of Molecular Medicine & Pathology, School of Medical Sciences, The University of AucklandDepartment of Molecular Medicine & Pathology, School of Medical Sciences, The University of AucklandAustralian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of QueenslandDepartment of Molecular Medicine & Pathology, School of Medical Sciences, The University of AucklandAbstract Pili of Group A Streptococcus (GAS) are surface-exposed structures involved in adhesion and colonisation of the host during infection. The major protein component of the GAS pilus is the T-antigen, which multimerises to form the pilus shaft. There are currently no licenced vaccines against GAS infections and the T-antigen represents an attractive target for vaccination. We have generated a multivalent vaccine called TeeVax1, a recombinant protein that consists of a fusion of six T-antigen domains. Vaccination with TeeVax1 produces opsonophagocytic antibodies in rabbits and confers protective efficacy in mice against invasive disease. Two further recombinant proteins, TeeVax2 and TeeVax3 were constructed to cover 12 additional T-antigens. Combining TeeVax1–3 produced a robust antibody response in rabbits that was cross-reactive to a full panel of 21 T-antigens, expected to provide over 95% vaccine coverage. These results demonstrate the potential for a T-antigen-based vaccine to prevent GAS infections.https://doi.org/10.1038/s41598-021-83673-4 |
| spellingShingle | Jacelyn M. S. Loh Tania Rivera-Hernandez Reuben McGregor Adrina Hema J. Khemlani Mei Lin Tay Amanda J. Cork Jeremy M. Raynes Nicole J. Moreland Mark J. Walker Thomas Proft A multivalent T-antigen-based vaccine for Group A Streptococcus Scientific Reports |
| title | A multivalent T-antigen-based vaccine for Group A Streptococcus |
| title_full | A multivalent T-antigen-based vaccine for Group A Streptococcus |
| title_fullStr | A multivalent T-antigen-based vaccine for Group A Streptococcus |
| title_full_unstemmed | A multivalent T-antigen-based vaccine for Group A Streptococcus |
| title_short | A multivalent T-antigen-based vaccine for Group A Streptococcus |
| title_sort | multivalent t antigen based vaccine for group a streptococcus |
| url | https://doi.org/10.1038/s41598-021-83673-4 |
| work_keys_str_mv | AT jacelynmsloh amultivalenttantigenbasedvaccineforgroupastreptococcus AT taniariverahernandez amultivalenttantigenbasedvaccineforgroupastreptococcus AT reubenmcgregor amultivalenttantigenbasedvaccineforgroupastreptococcus AT adrinahemajkhemlani amultivalenttantigenbasedvaccineforgroupastreptococcus AT meilintay amultivalenttantigenbasedvaccineforgroupastreptococcus AT amandajcork amultivalenttantigenbasedvaccineforgroupastreptococcus AT jeremymraynes amultivalenttantigenbasedvaccineforgroupastreptococcus AT nicolejmoreland amultivalenttantigenbasedvaccineforgroupastreptococcus AT markjwalker amultivalenttantigenbasedvaccineforgroupastreptococcus AT thomasproft amultivalenttantigenbasedvaccineforgroupastreptococcus AT jacelynmsloh multivalenttantigenbasedvaccineforgroupastreptococcus AT taniariverahernandez multivalenttantigenbasedvaccineforgroupastreptococcus AT reubenmcgregor multivalenttantigenbasedvaccineforgroupastreptococcus AT adrinahemajkhemlani multivalenttantigenbasedvaccineforgroupastreptococcus AT meilintay multivalenttantigenbasedvaccineforgroupastreptococcus AT amandajcork multivalenttantigenbasedvaccineforgroupastreptococcus AT jeremymraynes multivalenttantigenbasedvaccineforgroupastreptococcus AT nicolejmoreland multivalenttantigenbasedvaccineforgroupastreptococcus AT markjwalker multivalenttantigenbasedvaccineforgroupastreptococcus AT thomasproft multivalenttantigenbasedvaccineforgroupastreptococcus |